Ann: Update - AnteoTech signs manufacturing contract with Operon, page-3

AnteoTech signs EuGeni COVID-19 ART contract manufacturing agreement with Operon.
❖ AnteoTech to enhance Quality Management System (QMS) and seek MDSAP certification to
facilitate single audit process for major market regulatory authorities.
❖ Saliva use case on track for CE Mark update in June 2021.
AnteoTech Ltd (ASX: ADO) (“AnteoTech” or “the Company”) is pleased to announce that it has
finalised and signed a manufacturing contract for its COVID-19 Antigen Rapid Test (ART)1 with
Zaragoza (Spain) based contract manufacturer Operon.
The execution of the agreement follows the successful completion of the technology transfer in March,
the completion of several reel-to-reel lateral flow strip scaled up production runs including full
commercial sized run, and the quality agreement connecting AnteoTech’s ISO-13485 Quality
Assurance testing with the Operon manufactured COVID-19 ART. Under the terms of the
manufacturing agreement, AnteoTech and Operon have agreed to an exclusivity period of three
years, during which Operon has the first right of refusal to manufacture AnteoTech’s COVID-19 ART’s
to supply the European market, exercisable only if Operon has the capacity to produce the quantity
of EuGeni COVID-19 ART to meet AnteoTech’s European demand.